An interventional study of PRIMUS in Chronic Cluster Headache, sponsored by Salvia BioElectronics. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Salvia BioElectronics · Not applicable, Interventional, and Device feasibility
The purpose of this study is to demonstrate the safe use of the PRIMUS System in subjects with chronic cluster headache. This is a single-centre, open label, prospective, first in human study to collect initial clinical data on the PRIMUS system for the treatment of chronic cluster headache.
Main Inclusion Criteria:
Main Exclusion Criteria:
PRIMUS system
Device: PRIMUS
PRIMUS system
Safety Evaluation
The primary safety assessment is the incidence of serious procedure and/or device-related adverse events in all subjects at 30 days.
Time frame: 4 weeks
Safety Evaluation
The primary safety assessment is the incidence of serious procedure and/or device-related adverse events in all subjects at the end of the study.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Salvia BioElectronics